Quality of life study after precise liver radiation
Part of Cancer, Digestive system clinical trials.
This study follows people with liver cancer (hepatocellular carcinoma) to see how their quality of life changes after a focused form of radiation called stereotactic ablative radiation therapy. It does not appear to test a new drug—rather, it measures patient-reported well-being after treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have liver cancer confirmed by scan or biopsy
- You have 1 to 3 liver spots that can be treated with this precise radiation
- Your care team decides this radiation is appropriate for you after a group tumor review
- You are age 18 or older and can give informed consent
- You can answer study questionnaires in a reliable way (in person or by interview)
- You can have a planning CT scan with contrast dye (a contrast-enhanced CT)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a focused type of radiation (SBRT) given after liver surgery to reduce the chance the cancer comes back, when the tumor was removed with a very small “safety margin.” It compares this approach to standard follow-up and looks at whether it improves outcomes in people with hepatocellular carcinoma.
This trial studies how well people do—especially their quality of life—after SBRT radiation for primary kidney cancer that can’t be removed with surgery. It may help doctors understand which patients benefit most and what side effects to expect.
This trial studies a combination approach—special, image-guided radiation and liver procedures—for liver cancer patients who cannot have surgery. It may help shrink tumors while protecting liver function by using planned, targeted treatment.
This study compares a standard radiation dose plan versus a plan that adjusts the dose based on how the tumor responds to radiation-related measurements. It aims to improve how well stereotactic body radiation therapy (SBRT) treats liver cancer while keeping side effects manageable.
This trial studies how radiation therapy (SBRT) affects a DNA fragment in the blood called ctDNA in people with liver cancer. By tracking ctDNA changes, doctors hope to better understand how well the treatment is working and possibly predict outcomes earlier.
This study compares two nonsurgical procedures for liver cancer: stereotactic radiosurgery (focused radiation) and radiofrequency ablation (heat therapy). It is for people whose tumor is in a tricky spot near major blood vessels or other structures, making surgery difficult, and who have not received prior treatment.
Hear when a new Hepatocellular Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.